EMARA, Mohammed; INC.;THE BRIGHAM AND WOMEN'S HOSPITAL, INC.;ANDERSON, Paul;IVANOV, Pavel;THE BRIGHAM AND WOMENS HOSPITAL
发明人:
ANDERSON, Paul,IVANOV, Pavel,EMARA, Mohammed
申请号：
USUS2011/043400
公开号：
WO2012/006551A2
申请日:
2011.07.08
申请国别(地区):
US
年份:
2012
代理人:
摘要：
Provided herein are neuroprotective molecules containing a sequence of 25-35 contiguous nucleotides that is at least 80% identical to a contiguous sequence between nucleotide 1 and nucleotide 50 of a mature human tRNA and at least four contiguous guanosine-containing nucleotides, where the sequence of 25-35 contiguous nucleotides contains a D-loop stem structure, the at least four contiguous guanosine-containing nucleotides are located at the 5' end of the neuroprotective molecule, and the neuroprotective molecule contains at least one deoxyribonucleotide. Also provided are molecules containing a sequence of 25-35 contiguous nucleotides that is at least 80% identical to a contiguous sequence between nucleotide 1 and nucleotide 50 of a mature human tRNA selected from the group of tRAArg, tRNAAsp, tRNAGln, tRNAGlu, tRNAGly, tRNAHis, tRNAIle, tRNALeu, tRNALys, tRNAMet, tRNAPro, tRNASeC, tRNASer, tRNASup, tRNAThr, tRNATrp, tRNATyr, tRNAVal, tRNAAsn, and tRNAPhe； and at least four contiguous guanosine-containing nucleotides, where the sequence of 25-35 contiguous nucleotides contains a D-loop stem structure and the at least four contiguous guanosine-containing nucleotides are located at the 5' end of the neuroprotective molecule. Also provided are methods of inducing or increasing stress granule formation in a cell, decreasing protein translation in a cell, decrease stress-induced cell death, or treating a neurological disorder associated with neuron death in a subject using at least one of these neuroprotective molecules or a C-myc oligonucleotide. Also provided are methods of identifying a candidate translation inhibitory nucleic acid.La présente invention concerne des molécules neuroprotectrices contenant une séquence de 25-35 nucléotides contigus qui est au moins identique à 80 % à une séquence contiguë entre le nucléotide 1 et le nucléotide 50 d'un ARNt humain mature et au moins quatre nucléotides contigus contenant de la guanosine, dans lesquelles la séquence de 25
